"These studies are an exciting advancement of our knowledge of ViviGen," said Mark Moore, PhD, Chief Scientific Affairs Officer at LifeNet Health. "We developed ViviGen based on pre-clinical research that showed a cellular graft focused on viable, lineage-committed bone cells could result in a safe, clinically effective bone void filler.
The issues related to the transfer of technology for the production of the Sputnik V vaccine abroad and its supply to Argentina have been addressed with the active assistance from the Russian Direct Investment Fund, headed by Kirill Dmitriev, and the Russia-Argentina Business Council, headed by Andrey Guryev.
Northwell Health placed 81st in the country and is being honored for a commitment to workplace wellness and exceptional health and benefits for healthcare professionals.
